D. E. Shaw & Co. Inc. Sells 31,233 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

D. E. Shaw & Co. Inc. lessened its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 62.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,571 shares of the medical instruments supplier's stock after selling 31,233 shares during the period. D. E. Shaw & Co. Inc. owned about 0.08% of LeMaitre Vascular worth $1,711,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in LMAT. New York State Teachers Retirement System increased its stake in LeMaitre Vascular by 1.2% during the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock valued at $755,000 after acquiring an additional 100 shares during the period. Flputnam Investment Management Co. grew its holdings in shares of LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock worth $269,000 after purchasing an additional 102 shares in the last quarter. Norden Group LLC increased its position in shares of LeMaitre Vascular by 4.5% during the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 103 shares during the period. Blue Barn Wealth LLC raised its stake in shares of LeMaitre Vascular by 4.4% in the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock valued at $229,000 after purchasing an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH raised its stake in shares of LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock valued at $1,285,000 after purchasing an additional 112 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 4,399 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total transaction of $374,354.90. Following the sale, the chief executive officer now owns 1,827,003 shares of the company's stock, valued at $155,477,955.30. The trade was a 0.24% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 102,009 shares of company stock worth $8,721,836. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Stock Up 1.6%

LMAT traded up $1.28 during trading on Tuesday, hitting $82.68. The company's stock had a trading volume of 227,711 shares, compared to its average volume of 167,290. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 45.18, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86. The firm's 50 day moving average price is $84.07 and its two-hundred day moving average price is $92.18. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. During the same quarter last year, the business posted $0.44 earnings per share. The business's quarterly revenue was up 12.0% compared to the same quarter last year. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is 40.40%.

Analyst Ratings Changes

LMAT has been the subject of a number of analyst reports. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital boosted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $98.14.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.